Olaparib
| Evidence Level: L5 | Predicted Indications: 54 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Olaparib |
| DrugBank ID | DB09074 |
| Brand Names (EU) | Lynparza |
| Evidence Level | L5 |
| Predicted Indications | 54 |
| Top Prediction Score | 99.66% |
Approved Indication (EMA)
Ovarian cancer Lynparza is indicated as monotherapy for the: maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary perit
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | borderline epithelial tumor of ovary | 99.66% | DL |
| 2 | ovarian clear cell adenocarcinoma | 99.28% | DL |
| 3 | malignant dysgerminomatous germ cell tumor of ovary | 99.22% | DL |
| 4 | hereditary site-specific ovarian cancer syndrome | 99.12% | DL |
| 5 | female breast carcinoma | 99.09% | DL |
| 6 | gonadal germ cell tumor | 98.95% | DL |
| 7 | ovarian primitive germ cell tumor | 98.95% | DL |
| 8 | choriocarcinoma of ovary | 98.91% | DL |
| 9 | malignant sex cord stromal tumor of ovary | 98.79% | DL |
| 10 | ovarian neoplasm | 98.75% | DL |
| 11 | familial ovarian cancer | 98.74% | DL |
| 12 | hereditary breast ovarian cancer syndrome | 98.67% | DL |
| 13 | ovarian adenocarcinoma | 98.67% | DL |
| 14 | yolk sac tumor | 98.62% | DL |
| 15 | maligant granulosa cell tumor of ovary | 98.52% | DL |
| 16 | ovarian malignant mesothelioma | 98.36% | DL |
| 17 | malignant non-epithelial tumor of ovary | 98.28% | DL |
| 18 | ovarian cancer, susceptibility to, 1 | 98.27% | DL |
| 19 | ovarian adenosarcoma | 98.27% | DL |
| 20 | theca steroid-producing cell malignant tumor of ovary, not further specified | 98.24% | DL |
Showing top 20 of 54 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.